176 related articles for article (PubMed ID: 21902577)
1. Lenalidomide: a new treatment option for Castleman disease.
Szturz P; Adam Z; Chovancová J; Stehlíková O; Klabusay M; Rehák Z; Koukalová R; Krejčí M; Pour L; Zahradová L; Hájek R; Mayer J
Leuk Lymphoma; 2012 Oct; 53(10):2089-91. PubMed ID: 21902577
[No Abstract] [Full Text] [Related]
2. Salvage lenalidomide in four rare oncological diseases.
Szturz P; Adam Z; Rehak Z; Koukalova R; Kren L; Moulis M; Krejcí M; Mayer J
Tumori; 2013; 99(5):e251-6. PubMed ID: 24362880
[TBL] [Abstract][Full Text] [Related]
3. [PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review].
Adam Z; Szturz P; Koukalová R; Řehák Z; Pour L; Krejčí M; Šmardová L; Eid M; Volfová P; Čermáková Z; Křen L; Sokol F; Hanke I; Michalková E; Král Z; Mayer J
Vnitr Lek; 2015 Mar; 61(3):251-9. PubMed ID: 25873122
[TBL] [Abstract][Full Text] [Related]
4. Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Broccoli A; Pellegrini C; Celli M; Argnani L; Agostinelli C; Pileri S; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e119-22. PubMed ID: 24629851
[No Abstract] [Full Text] [Related]
5. The management of Castleman disease.
Lomas OC; Streetly M; Pratt G; Cavet J; Royston D; Schey S; Ramasamy K;
Br J Haematol; 2021 Nov; 195(3):328-337. PubMed ID: 34340261
[No Abstract] [Full Text] [Related]
6. Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.
Zhou X; Wei J; Lou Y; Xu G; Yang M; Liu H; Mao L; Tong H; Jin J
Front Med; 2017 Jun; 11(2):287-292. PubMed ID: 28367597
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of lenalidomide in non-Hodgkin lymphoma.
Galanina N; Petrich A; Nabhan C
Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide-associated hemolytic anemia.
Lim MY; Raval JS; Richards KL; Zeidner JF; Foster MC
Leuk Lymphoma; 2015; 56(9):2717-9. PubMed ID: 25644743
[No Abstract] [Full Text] [Related]
9. [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Adam Z; Pour L; Krejčí M; Zahradová L; Szturz P; Koukalová R; Rehák Z; Nebeský T; Hájek R; Král Z; Mayer J
Vnitr Lek; 2012 Nov; 58(11):856-66. PubMed ID: 23256832
[TBL] [Abstract][Full Text] [Related]
10. Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases.
Zhao X; Shi R; Jin X; Zheng J
J Am Acad Dermatol; 2011 Aug; 65(2):430-432. PubMed ID: 21763571
[No Abstract] [Full Text] [Related]
11. Castleman disease presenting with ophthalmic signs and symptoms.
Kurokawa T; Suzuki S; Kawaguchi K; Fujisawa N; Yoshimura N
Am J Ophthalmol; 1999 Jul; 128(1):114-6. PubMed ID: 10482111
[TBL] [Abstract][Full Text] [Related]
12. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic multicentric Castleman disease of TAFRO subtype.
Godfrey K; Harris E; Moss H; Martin-Cabrera P
Br J Haematol; 2022 Feb; 196(3):461. PubMed ID: 34618353
[No Abstract] [Full Text] [Related]
14. [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Adam Z; Szturz P; Krejčí M; Koukalová R; Michalková E; Řehák Z; Pourová E; Pour L; Volfová P; Sandecká V; Čermáková Z; Křen L; Sokol F; Hanke I; Penka I; Petrášová H; Ševčíková S; Král Z; Mayer J
Vnitr Lek; 2016 Apr; 62(4):287-98. PubMed ID: 27250606
[TBL] [Abstract][Full Text] [Related]
15. Widespread Castleman disease: CT findings.
Gossios K; Nikolaides C; Bai M; Fountzilas G
Eur Radiol; 1996; 6(1):95-8. PubMed ID: 8797962
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Vallet S; Palumbo A; Raje N; Boccadoro M; Anderson KC
Leuk Lymphoma; 2008 Jul; 49(7):1238-45. PubMed ID: 18452080
[TBL] [Abstract][Full Text] [Related]
18. Castleman-Kojima disease in a South Asian adolescent.
Koduri PR; Parvez M; Kaza S; Pappu P; Anuradha S
J Clin Exp Hematop; 2014; 54(2):163-6. PubMed ID: 25318950
[No Abstract] [Full Text] [Related]
19. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Denman J; Manavi K; Cook M
Int J STD AIDS; 2017 Sep; 28(10):1045-1047. PubMed ID: 28632471
[TBL] [Abstract][Full Text] [Related]
20. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Carras S; Regny C; Peoc'h M; Gervasoni J; Gressin R; Cahn JY; Molina L
Leuk Lymphoma; 2015; 56(10):2986-8. PubMed ID: 25676034
[No Abstract] [Full Text] [Related]
[Next] [New Search]
